Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of December 31, 2024, Kiromic BioPharma, Inc. has 1.53M shares outstanding.

As of December 31, 2024, Kiromic BioPharma, Inc. maintains a current ratio of 0.16, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -115.74, indicating conservative leverage, while an interest coverage ratio of -5.78 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -259.72, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 37.25, a quick read on workforce productivity versus industry peers.

As of the close on October 5, 2026, Kiromic BioPharma, Inc.'s stock has declined approximately 98.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.79.

Over the twelve months ended December 31, 2024, Kiromic BioPharma, Inc. generated - - in revenue and converted that into -26.90M in net income, yielding earnings per share of -18.27. EBITDA reached -21.54M, while operating income came in at -23.77M.

As of December 31, 2024, Kiromic BioPharma, Inc. holds 1.14M in cash and equivalents against 14.57M in total debt, resulting in a net debt position of 12.52M. Total book value stands at -12.59M, with working capital of -17.60M providing operational flexibility.

Kiromic BioPharma, Inc. produced -19.46M in operating cash flow over the twelve months ended December 31, 2024. After subtracting -366,000.00 in capital expenditures, free cash flow totaled -19.82M - equivalent to -13.46 per share.

Kiromic BioPharma, Inc.'s most recent stock split took place on March 13, 2023 with a 30:1 split ratio.